810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up) | Zendy

AI Assistant Blog Pricing

810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.